pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['keynote,671', 'keynote-671']
efficacy pathologic responses keynote-671 #asco23 mpr 30.2% vs 11% cr: 18.1% vs. 4%
subgroup analysis according to mpr and cr supports the impact on efs seen in other neoadjuvabt trials. 
MD, PhD - Thoracic Oncologist. Precision Medicine Consultant & Co-Founder PxMedica and Medical Consultant @bradfordhill_cl.